Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012)

Acadia Pharmaceuticals (ACAD) posted quarterly Current Leases of $3000.0 for Q3 2012, down 76.92% quarter-over-quarter from $13000.0 in Q2 2012.

Acadia Pharmaceuticals (ACAD) Current Leases (2011 - 2012) Analysis & Trends

Acadia Pharmaceuticals' Current Leases history runs 2 years deep, the most recent figure standing at $3000.0 for Q3 2012.

In Q3 2012, Current Leases changed N/A year-over-year to $3000.0; the TTM figure through Sep 2012 stood at $3000.0 (changed N/A YoY), while the FY2011 annual figure was $32000.0, changed N/A from the prior year.
Current Leases for Q3 2012 stood at $3000.0, down from $13000.0 in the prior quarter.
The five-year high for Current Leases was $32000.0 in Q4 2011, with the low at $3000.0 in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	11.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	16.75 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	21.95 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.24 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	45.93 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.27 Mn
10	Acadia Pharmaceuticals	4.86 Bn	3.90 Bn	279.64 Mn	-

Download Data